149 related articles for article (PubMed ID: 36301958)
1. A Systematic Review on the Interest of Drug-tolerant Assay in the Monitoring of Inflammatory Bowel Disease.
Barrau M; Duprat M; Veyrard P; Tournier Q; Williet N; Marc Phelip J; Waeckel L; Cheifetz AS; Papamichael K; Roblin X; Paul S
J Crohns Colitis; 2023 Apr; 17(4):633-643. PubMed ID: 36301958
[TBL] [Abstract][Full Text] [Related]
2. Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor.
Vande Casteele N; Abreu MT; Flier S; Papamichael K; Rieder F; Silverberg MS; Khanna R; Okada L; Yang L; Jain A; Cheifetz AS
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):465-467.e2. PubMed ID: 33421628
[TBL] [Abstract][Full Text] [Related]
3. Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
Chanchlani N; Lin S; Auth MK; Lee CL; Robbins H; Looi S; Murugesan SV; Riley T; Preston C; Stephenson S; Cardozo W; Sonwalkar SA; Allah-Ditta M; Mansfield L; Durai D; Baker M; London I; London E; Gupta S; Di Mambro A; Murphy A; Gaynor E; Jones KDJ; Claridge A; Sebastian S; Ramachandran S; Selinger CP; Borg-Bartolo SP; Knight P; Sprakes MB; Burton J; Kane P; Lupton S; Fletcher A; Gaya DR; Colbert R; Seenan JP; MacDonald J; Lynch L; McLachlan I; Shields S; Hansen R; Gervais L; Jere M; Akhtar M; Black K; Henderson P; Russell RK; Lees CW; Derikx LAAP; Lockett M; Betteridge F; De Silva A; Hussenbux A; Beckly J; Bendall O; Hart JW; Thomas A; Hamilton B; Gordon C; Chee D; McDonald TJ; Nice R; Parkinson M; Gardner-Thorpe H; Butterworth JR; Javed A; Al-Shakhshir S; Yadagiri R; Maher S; Pollok RCG; Ng T; Appiahene P; Donovan F; Lok J; Chandy R; Jagdish R; Baig D; Mahmood Z; Marsh L; Moss A; Abdulgader A; Kitchin A; Walker GJ; George B; Lim YH; Gulliver J; Bloom S; Theaker H; Carlson S; Cummings JRF; Livingstone R; Beale A; Carter JO; Bell A; Coulter A; Snook J; Stone H; Kennedy NA; Goodhand JR; Ahmad T;
Aliment Pharmacol Ther; 2022 Oct; 56(8):1250-1263. PubMed ID: 36039036
[TBL] [Abstract][Full Text] [Related]
4. Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease.
Tournier Q; Paul S; Williet N; Berger AE; Veyrard P; Boschetti G; Le Roy B; Killian M; Phelip JM; Flourie B; Nancey S; Roblin X
Aliment Pharmacol Ther; 2021 Jun; 53(11):1190-1200. PubMed ID: 33872404
[TBL] [Abstract][Full Text] [Related]
5. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].
Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T
Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355
[TBL] [Abstract][Full Text] [Related]
6. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors.
Bodio C; Grossi C; Pregnolato F; Favalli EG; Biggioggero M; Marchesoni A; Murgo A; Filippini M; Migliorini P; Caporali R; Pellerito R; Ciccia F; Sarzi-Puttini P; Perosa F; Paolazzi G; Hollan I; Bendtzen K; Meroni PL; Borghi MO
Autoimmun Rev; 2020 May; 19(5):102509. PubMed ID: 32173513
[TBL] [Abstract][Full Text] [Related]
7. Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease.
Kim JY; Lee Y; Choe BH; Kang B
Gut Liver; 2021 Jul; 15(4):588-598. PubMed ID: 33024062
[TBL] [Abstract][Full Text] [Related]
8. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
9. Distinct Association of Serum Vitamin D Concentration with Disease Activity and Trough Levels of Infliximab and Adalimumab during Inflammatory Bowel Disease Treatment.
Mechie NC; Mavropoulou E; Ellenrieder V; Kunsch S; Cameron S; Amanzada A
Digestion; 2020; 101(6):761-770. PubMed ID: 31536991
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease.
Stallhofer J; Guse J; Kesselmeier M; Grunert PC; Lange K; Stalmann R; Eckardt V; Stallmach A
Int J Colorectal Dis; 2023 Feb; 38(1):54. PubMed ID: 36840779
[TBL] [Abstract][Full Text] [Related]
11. High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases.
Sasson AN; Ananthakrishnan AN
Dig Dis Sci; 2022 Jul; 67(7):3124-3128. PubMed ID: 34117949
[TBL] [Abstract][Full Text] [Related]
12. Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases.
Grinman AB; de Souza MDGC; Bouskela E; Carvalho ATP; de Souza HSP
Medicine (Baltimore); 2020 Mar; 99(10):e19359. PubMed ID: 32150077
[TBL] [Abstract][Full Text] [Related]
13. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
14. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
Roblin X; Williet N; Boschetti G; Phelip JM; Del Tedesco E; Berger AE; Vedrines P; Duru G; Peyrin-Biroulet L; Nancey S; Flourie B; Paul S
Gut; 2020 Jul; 69(7):1206-1212. PubMed ID: 31980448
[TBL] [Abstract][Full Text] [Related]
15. Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with inflammatory bowel disease.
Theodoraki E; Orfanoudaki E; Foteinogiannopoulou K; Andreou NP; Gazouli M; Koutroubakis IE
Int J Colorectal Dis; 2022 Mar; 37(3):639-646. PubMed ID: 35013823
[TBL] [Abstract][Full Text] [Related]
16. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
17. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy.
Nigam GB; Bhandare AP; Antoniou GA; Limdi JK
Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):346-357. PubMed ID: 32889976
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits.
Bertin D; Serrero M; Grimaud JC; Desjeux A; Desplat-Jégo S
Cytokine; 2020 Feb; 126():154859. PubMed ID: 31629989
[TBL] [Abstract][Full Text] [Related]
19. BMI is important in predicting the loss of response in inflammatory bowel disease patients on tumour necrosis factor-α inhibitors.
Chuck W; Shadbolt BF; Nordin F; Subramaniam K
Eur J Gastroenterol Hepatol; 2022 Jun; 34(6):622-629. PubMed ID: 35352694
[TBL] [Abstract][Full Text] [Related]
20. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.
Gil-Candel M; Gascón-Cánovas JJ; Urbieta-Sanz E; Rentero-Redondo L; Onteniente-Candela M; Iniesta-Navalón C
Int J Clin Pharm; 2020 Apr; 42(2):500-507. PubMed ID: 32006141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
